Status: Recruiting
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7. The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants with locally advanced or metastatic solid tumors and as combination therapy with fulvestrant in participants with advanced or metastatic ER+, HER2- breast cancer.
Participants needed: 160
Trial details
Phase: Phase 1Age: 18-99Biological sex: AllType: InterventionalSponsor: IDEAYA BiosciencesUpdated: Jun 16, 2026Locations: 11
Eligibility criteria
Part 1A - Participants with advanced or metastatic ER+, HER2- breast cancer, NSC... [+8]
Known symptomatic brain metastases or leptomeningeal metastasis [+8]